Jump to main content
Jump to site search

Issue 23, 2018
Previous Article Next Article

Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review

Author affiliations

Abstract

Flavopiridol (alvocidib) is a synthetic flavonoid based on the extract from an Indian plant developed for potential treatment of cancer whose first clinical trials were initiated in 1994 as a frontline combination therapy for leukaemia. It is a potent Cyclin Dependent Kinase (CDK) inhibitor with preferential activity against CDK9. Several phase I and II trials using flavopiridol as a single agent and in combination with standard chemotherapeutic regimens and various tumor types are ongoing. Moreover, the combination of flavopiridol with gemcitabine, imatinib mesylate, SN-38 (the active metabolite of CPT-11) and doxorubicin show synergistic therapeutic effect in inducing mortality of cancer cells. Present study enlightens the individual and combined therapeutic and toxic profiles of flavopiridol. The synthesis, mechanism of action, preclinical and clinical outcomes of flavopiridol till date have been discussed in the current study.

Graphical abstract: Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review

Back to tab navigation

Publication details

The article was received on 23 Aug 2018, accepted on 17 Oct 2018 and first published on 18 Oct 2018


Article type: Perspective
DOI: 10.1039/C8NJ04306J
Citation: New J. Chem., 2018,42, 18500-18507
  •   Request permissions

    Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review

    A. Deep, R. K. Marwaha, M. G. Marwaha, Jyoti, R. Nandal and A. K. Sharma, New J. Chem., 2018, 42, 18500
    DOI: 10.1039/C8NJ04306J

Search articles by author

Spotlight

Advertisements